RU95117922A - COMPOSITION AND METHODS OF DELIVERY OF GENETIC MATERIAL - Google Patents

COMPOSITION AND METHODS OF DELIVERY OF GENETIC MATERIAL

Info

Publication number
RU95117922A
RU95117922A RU95117922/14A RU95117922A RU95117922A RU 95117922 A RU95117922 A RU 95117922A RU 95117922/14 A RU95117922/14 A RU 95117922/14A RU 95117922 A RU95117922 A RU 95117922A RU 95117922 A RU95117922 A RU 95117922A
Authority
RU
Russia
Prior art keywords
nucleic acid
hiv
acid molecule
sequence encoding
virus
Prior art date
Application number
RU95117922/14A
Other languages
Russian (ru)
Other versions
RU2174845C2 (en
Inventor
Б.Вейнер Дэвид
В.Вилльямс Вилльям
ВАНГ Бин
Р.Кони Лесли
Дж.Мерва Майкл
Р.Зуравски Винсент (младший)
Original Assignee
Б.Вейнер Дэвид
В.Вилльямс Вилльям
ВАНГ Бин
Р.Кони Лесли
Дж.Мерва Майкл
Р.Зуравски Винсент (младший)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Б.Вейнер Дэвид, В.Вилльямс Вилльям, ВАНГ Бин, Р.Кони Лесли, Дж.Мерва Майкл, Р.Зуравски Винсент (младший) filed Critical Б.Вейнер Дэвид
Publication of RU95117922A publication Critical patent/RU95117922A/en
Application granted granted Critical
Publication of RU2174845C2 publication Critical patent/RU2174845C2/en

Links

Claims (48)

1. Способ введения в клетки индивидуума генетического материала, отличающийся тем, что осуществляют: а) контактирование клеток индивидуума с усилителем функции полинуклеотида; b) введение в клетки индивидуума молекулы нуклеиновой кислоты, причем молекула нуклеиновой кислоты не содержит частиц ретровируса.1. The method of introducing into the cells of an individual genetic material, characterized in that they carry out: a) contacting the cells of the individual with an enhancer of polynucleotide function; b) introducing into the cells of an individual a nucleic acid molecule, wherein the nucleic acid molecule does not contain retrovirus particles. 2. Способ по п. 1, отличающийся тем, что усилитель функции полинуклеотида представлен бупивакаином. 2. The method according to p. 1, characterized in that the polynucleotide function enhancer is represented by bupivacaine. 3. Способ по п. 1, отличающийся тем, что молекула нуклеиновой кислоты включает нуклеотидную последовательность, кодирующую белок и операбельно связанную с регуляторными последовательностями. 3. The method according to p. 1, characterized in that the nucleic acid molecule comprises a nucleotide sequence encoding a protein and operably linked to regulatory sequences. 4. Способ по п. 1, отличающийся тем, что молекула нуклеиновой кислоты включает нуклеотидную последовательность, кодирующую белок, в состав которого входит по меньшей мере один эпитоп, идентичный или по существу аналогичный эпитопу антигена, против которого желателен иммунный ответ, причем нуклеотидная последовательность операбельно связана с регуляторными последовательностями. 4. The method according to p. 1, characterized in that the nucleic acid molecule comprises a nucleotide sequence encoding a protein, which includes at least one epitope that is identical or substantially similar to the epitope of the antigen against which an immune response is desired, the nucleotide sequence being operable linked to regulatory sequences. 5. Способ по п. 1, отличающийся тем, что молекула нуклеиновой кислоты включает нуклеотидную последовательность, кодирующую белок, в состав которого входит по крайней мере один эпитоп, идентичный или по существу подобный эпитопу антигена патогена. 5. The method of claim 1, wherein the nucleic acid molecule comprises a nucleotide sequence encoding a protein that comprises at least one epitope that is identical or substantially similar to an epitope of a pathogen antigen. 6. Способ по п. 5, отличающийся тем, что усилитель функции полинуклеотида представлен бупивакаином. 6. The method according to p. 5, characterized in that the polynucleotide function enhancer is represented by bupivacaine. 7. Способ по п. 5, отличающийся тем, что молекула нуклеиновой кислоты представлена молекулой ДНК. 7. The method according to p. 5, characterized in that the nucleic acid molecule is a DNA molecule. 8. Способ по п. 5, отличающийся тем, что белок представлен антигеном патогена или его фрагментом. 8. The method according to p. 5, characterized in that the protein is represented by a pathogen antigen or fragment thereof. 9. Способ по п. 5, отличающийся тем, что молекулу нуклеиновой кислоты вводят внутримышечно. 9. The method according to p. 5, characterized in that the nucleic acid molecule is administered intramuscularly. 10. Способ по п. 5, отличающийся тем, что патоген представлен вирусом, выбранным из группы, включающей вирус иммунодефицита человека (ВИЧ); вирус Т-клеточного лейкоза человека (TPLV), вирус гриппа, вирус гепатита A (HAV), вирус гепатита В (HBV), вирус гепатита С (HCV), вирус папилломы человека (HPV), вирус простого герпеса 1 (HSV1), вирус простого герпеса 2 (HSV2), цитомегаловирус (CMV), вирус Энштейна-Барра (TBV), риновирус и коронавирус. 10. The method according to p. 5, characterized in that the pathogen is a virus selected from the group comprising the human immunodeficiency virus (HIV); human T-cell leukemia virus (TPLV), influenza virus, hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV), herpes simplex virus 1 (HSV1), virus herpes simplex 2 (HSV2), cytomegalovirus (CMV), Einstein-Barr virus (TBV), rhinovirus and coronavirus. 11. Способ по п. 5, отличающийся тем, что патоген представлен ВИЧ и молекула нуклеиновой кислоты включает нуклеотидную последовательность, кодирующую белок ВИЧ. 11. The method according to p. 5, characterized in that the pathogen is HIV and the nucleic acid molecule comprises a nucleotide sequence encoding an HIV protein. 12. Способ по п. 5, отличающийся тем, что патоген представлен ВИЧ и молекула нуклеиновой кислоты включает нуклеотидные последовательности, кодирующие более одного структурного белка ВИЧ. 12. The method according to p. 5, characterized in that the pathogen is represented by HIV and the nucleic acid molecule includes nucleotide sequences encoding more than one structural protein of HIV. 13. Способ по п. 5, отличающийся тем, что патоген представлен ВИЧ и молекула нуклеиновой кислоты включает нуклеотидные последовательности, кодирующие более одного регулярного белка ВИЧ. 13. The method of claim 5, wherein the pathogen is HIV and the nucleic acid molecule comprises nucleotide sequences encoding more than one regular HIV protein. 14. Способ по п. 5, отличающийся тем, что по крайней мере молекулы двух или более разных нуклеиновых кислот вводят в разные клетки индивидуума, причем разные нуклеиновые кислоты включают каждая нуклеотидные последовательности, кодирующие один или более антигенов патогена одного и того же патогена. 14. The method according to p. 5, characterized in that at least two or more different nucleic acid molecules are introduced into different cells of the individual, and different nucleic acids include each nucleotide sequence encoding one or more pathogen antigens of the same pathogen. 15. Способ по п. 5, отличающийся тем, что усилитель функции полинуклеотида и молекулу нуклеиновой кислоты вводят одновременно. 15. The method according to p. 5, characterized in that the polynucleotide function enhancer and the nucleic acid molecule are administered simultaneously. 16. Способ по п. 5, отличающийся тем, что индивидуумом является человек; усилитель функции полинуклеотида представлен бупивакаином; патоген представлен вирусом иммунодефицита человека; молекула нуклеиновой кислоты представлена ДНК и включает ДНК последовательность, кодирующую структурные белки gаg и ро1 ВИЧ с делецией psi, причем кодирующая gag и ро1 ДНК последовательность операбельно связана с усилителем вируса саркомы Paуса, непосредственно ранним промотором цитомегаловируса и малым сигналом полиаденилирования SV 40 и необязательно точкой начала репликации SV 40. 16. The method according to p. 5, characterized in that the individual is a person; an enhancer of polynucleotide function is represented by bupivacaine; the pathogen is a human immunodeficiency virus; the nucleic acid molecule is represented by DNA and includes a DNA sequence encoding the HIV gag and po1 structural proteins with a psi deletion; moreover, the gag and po1 DNA coding sequence is operably linked to a Paus sarcoma virus enhancer, directly an early cytomegalovirus promoter and a small SV 40 polyadenylation signal and optionally a start point SV 40 replication. 17. Способ по п. 16, отличающийся тем, что ДНК последовательность дополнительно включает rev-респондирующий элемент ВИЧ и делецию интегразы ВИЧ. 17. The method according to p. 16, wherein the DNA sequence further comprises a rev-responsive HIV element and a deletion of HIV integrase. 18. Способ по п. 17, отличающийся тем, что ДНК последовательность дополнительно включает сплайс-акцептор ВИЧ. 18. The method of claim 17, wherein the DNA sequence further comprises an HIV splice acceptor. 19. Способ по п. 16, отличающийся тем, что ДНК молекула дополнительно включает ДНК последовательность, кодирующую последовательность, дополнительно содержащую ВИЧ rev, операбельно связанный с промотором SV 40 и малым сигналом полиаденилирования SV 40 и необязательно с точкой начала репкации SV 40. 19. The method of claim 16, wherein the DNA molecule further comprises a DNA sequence encoding a sequence further comprising HIV rev, operably linked to the SV 40 promoter and the SV 40 small polyadenylation signal and optionally to the SV 40 replication start point. 20. Способ по п. 19, отличающийся тем, что кодирующая rev ДНК последовательность кодирует, кроме того, vpu ВИЧ и env ВИЧ. 20. The method according to p. 19, characterized in that the coding rev DNA sequence encodes, in addition, vpu HIV and env HIV. 21. Способ по п. 19, отличающийся тем, что ДНК последовательность, кодирующая gag и ро1, дополнительно включает rev-респондирующий элемент ВИЧ и делецию интегразы ВИЧ. 21. The method of claim 19, wherein the DNA sequence encoding gag and po1 further comprises a rev-responsive HIV element and a deletion of HIV integrase. 22. Способ по п. 21, отличающийся тем, что ДНК последовательность, кодирующая gag и ро1, дополнительно включает сплайс-акцептор ВИЧ. 22. The method according to p. 21, characterized in that the DNA sequence encoding gag and po1, further includes a splice acceptor of HIV. 23. Способ по п. 5, отличающийся тем, что индивидуумом является человек; усилитель функции полинуклеотида представлен бупиванаином; патоген представлен вирусом иммунодефицита человека; молекулами нуклеиновой кислоты является ДНК и содержит ДНК-последовательность, кодирующую rev-, vpu и env-белки HIV, операбельно связанную с усилителем вируса саркомы Рауса, непосредственно ранним промотором цитомегаловируса и малым сигналом полиаденилирования SV 40 и необязательно точкой начала репликации SV 40. 23. The method according to p. 5, characterized in that the individual is a person; an enhancer of polynucleotide function is represented by bupivanain; the pathogen is a human immunodeficiency virus; the nucleic acid molecule is DNA and contains a DNA sequence encoding HIV rev-, vpu and env proteins, operably linked to an Routh sarcoma virus enhancer, directly an early cytomegalovirus promoter, and a small polyadenylation signal SV40 and optionally SV40 replication origin. 24. Способ по п. 5, отличающийся тем, что индивидуумом является человек; усилитель функции полинуклеотида представлен бупивакаином; патоген представлен вирусом иммунодефицита человека; молекулы двух различных ДНК вводят в разные клетки индивидуума; молекула одной из нуклеиновых кислот является ДНК и включает ДНК последовательность, кодирующую структурные белки gag и ро1 ВИЧ с делецией psi, причем ДНК последовательность, кодирующая gag и pol, операбельно связана с усилителем вируса саркомы Рауса, непосредственно ранним промотором цитомегаловируса и малым сигналом полиаденилирования SV 40 и необязательно с точкой начала репликации SV 40; молекула другой нуклеиновой кислоты является ДНК и включает ДНК последовательность, кодирующую ВИЧ белки rev, vpu и env, операбельно связанные с усилителем вируса саркомы Рауса, непосредственно ранним промотором цитомегаловируса и малым сигналом полиаденилирования SV 40 и необязательно с точкой начала репликации SV 40. 24. The method according to p. 5, characterized in that the individual is a person; an enhancer of polynucleotide function is represented by bupivacaine; the pathogen is a human immunodeficiency virus; molecules of two different DNA are introduced into different cells of an individual; the molecule of one of the nucleic acids is DNA and includes a DNA sequence encoding the HIV gag and po1 structural proteins with a psi deletion, and the DNA sequence encoding gag and pol is operably linked to an Routh sarcoma virus enhancer, a direct early cytomegalovirus promoter and a small SV 40 polyadenylation signal and optionally with an SV 40 origin of replication; the other nucleic acid molecule is DNA and includes a DNA sequence encoding the HIV proteins rev, vpu, and env operably linked to an Routh sarcoma virus enhancer, directly an early cytomegalovirus promoter, and a small SV 40 polyadenylation signal and optionally with an SV 40 origin of replication. 25. Способ по п. 5, отличающийся тем, что осуществляют введение в клетки человека молекул двух разных нуклеиновых кислот, при это молекула каждой нуклеиновой кислоты включает нуклеотидную последовательность, кодирующую белок, содержащий по меньшей мере один эпитоп, идентичный или по существу аналогичный эпитопу по меньшей мере одного антигена ВИЧ операбельно связанную с регуляторными последовательностями, причем нуклеотидные последовательности способны экспрессироваться в клетках, нуклеотидные последовательности каждой из двух разных нуклеиновых кислот кодируют различные белки, указанные белки имеют по меньшей мере один эпитоп, идентичный или по существу аналогичный эпитопу по меньшей мере одного белка ВИЧ, кодируемого генами ВИЧ, выбранными из группы, включающей gag, ро1 и env. 25. The method according to p. 5, characterized in that the introduction into human cells of molecules of two different nucleic acids, the molecule of each nucleic acid comprising a nucleotide sequence encoding a protein containing at least one epitope that is identical or essentially similar to the epitope according to at least one HIV antigen operably linked to regulatory sequences, the nucleotide sequences being able to be expressed in cells, the nucleotide sequences of each of two different nucleic acids encode different proteins, these proteins have at least an epitope identical or substantially similar to an epitope of at least one HIV protein encoded by HIV genes selected from the group consisting of gag, PO1 and env. 26. Способ по п. 1, отличающийся тем, что молекула нуклеиновой кислоты включает нуклеотидную последовательность, кодирующую целевой белок, содержащий эпитоп, идентичный или по существу подобный эпитопу белка, ассоциированного с клетками, характеризующими заболевание. 26. The method according to p. 1, characterized in that the nucleic acid molecule comprises a nucleotide sequence encoding a target protein containing an epitope that is identical or substantially similar to the epitope of a protein associated with cells characterizing the disease. 27. Способ по п. 26, отличающийся тем, что усилитель функции полинуклеотида представлен бупивакаином. 27. The method according to p. 26, wherein the polynucleotide function enhancer is represented by bupivacaine. 28. Способ по п. 26, отличающийся тем, что заболевание характеризуется гиперпролиферацией клеток. 28. The method according to p. 26, characterized in that the disease is characterized by hyperproliferation of cells. 29. Способ по п. 26, отличающийся тем, что заболевание является аутоиммунным заболеванием. 29. The method according to p. 26, wherein the disease is an autoimmune disease. 30. Способ по п. 26, отличающийся тем, что молекула нуклеиновой кислоты является молекулой ДНК. 30. The method according to p. 26, wherein the nucleic acid molecule is a DNA molecule. 31. Способ по п. 26, отличающийся тем, что молекулу нуклеиновой кислоты вводят внутримышечно. 31. The method according to p. 26, wherein the nucleic acid molecule is administered intramuscularly. 32. Способ по п. 26, отличающийся тем, что молекула нуклеиновой кислоты включает нуклеотидную последовательность, кодирующую целевой белок, выбранный из группы, включающей белковые продукты онкогенов myb, myc, fyn, ras, sarc, neu и trk; белковые продукты транслокационного гена bcl/ab1; Р53; EGRF; вариабельные области антител, полученных с помощью В-клеточных лимфом, и вариабельные области Т-клеточных рецепторов Т-клеточных лимфом. 32. The method according to p. 26, wherein the nucleic acid molecule comprises a nucleotide sequence encoding a target protein selected from the group consisting of protein products of the oncogenes myb, myc, fyn, ras, sarc, neu and trk; protein products of the bcl / ab1 translocation gene; P53; EGRF; the variable regions of antibodies obtained using B-cell lymphomas; and the variable regions of T-cell receptors of T-cell lymphomas. 33. Способ по п. 26, отличающийся тем, что белок выбирают из группы, включающей вариабельные области антител, участвующих в опосредуемом В-клетками аутоиммунном заболевании, и вариабельные области Т-клеточных рецепторов, участвующих в опосредуемом Т-клетками аутоиммунном заболевании. 33. The method according to p. 26, wherein the protein is selected from the group comprising variable regions of antibodies involved in B-cell-mediated autoimmune disease and variable regions of T-cell receptors involved in T-cell-mediated autoimmune disease. 34. Способ по п. 1, отличающийся тем, что молекула нуклеиновой кислоты включает нуклеотидную последовательность, кодирующую белок, присутствие которого будет компенсировать отсутствующий, нефункциональный или частично функционирующий белок или обеспечивать терапевтический эффект у индивидуума. 34. The method according to p. 1, characterized in that the nucleic acid molecule comprises a nucleotide sequence encoding a protein, the presence of which will compensate for the missing, non-functional or partially functioning protein or provide a therapeutic effect in an individual. 35. Способ по п. 34, отличающийся тем, что усилитель функции полинуклеотида представлен бупивакаином. 35. The method of claim 34, wherein the polynucleotide function enhancer is bupivacaine. 36. Способ по п. 34, отличающийся тем, что молекула нуклеиновой кислоты представлена молекулой ДНК. 36. The method according to p. 34, characterized in that the nucleic acid molecule is a DNA molecule. 37. Способ по п. 34, отличающийся тем, что молекула нуклеиновой кислоты вводится внутримышечно. 37. The method according to p. 34, wherein the nucleic acid molecule is administered intramuscularly. 38. Способ по п. 34, отличающийся тем, что молекула нуклеиновой кислоты включает нуклеотидную последовательность, кодирующую белок, выбранный из группы, состоящей из ферментов, структурных белков, цитокинов, лимфокинов и факторов роста. 38. The method of claim 34, wherein the nucleic acid molecule comprises a nucleotide sequence encoding a protein selected from the group consisting of enzymes, structural proteins, cytokines, lymphokines and growth factors. 39. Фармацевтическая композиция, содержащая молекулу нуклеиновой кислоты, представленную молекулой ДНК, которая включает ДНК-последовательность, кодирующую белок, необязательно связанную с регуляторными элементами; усилитель функции полинуклеотида. 39. A pharmaceutical composition comprising a nucleic acid molecule represented by a DNA molecule, which includes a DNA sequence encoding a protein, optionally associated with regulatory elements; polynucleotide function enhancer. 40. Композиция по п. 39, отличающаяся тем, что молекула нуклеиновой кислоты включает нуклеотидную последовательность, кодирующую белок, выбранный из группы, состоящей из белков, включающих по крайней мере один эпитоп, идентичный или по существу подобный эпитопу антигена патогена; белков, содержащих эпитоп, идентичный или по существу подобный эпитопу белка, ассоциированного с гиперпролиферирующими клетками; белков, содержащих эпитоп, идентичный или по существу подобный эпитопу белка, ассоциированного с клетками, характеризующими аутоиммунное заболевание; белков, присутствие которых будет компенсировать отсутствующий нефункциональный или частично функционирующий белок у индивидуума; и белков, обеспечивающих терапевтический эффект у индивидуума. 40. The composition of claim 39, wherein the nucleic acid molecule comprises a nucleotide sequence encoding a protein selected from the group consisting of proteins comprising at least one epitope that is identical or substantially similar to an epitope of a pathogen antigen; proteins containing an epitope that is identical or substantially similar to an epitope of a protein associated with hyperproliferating cells; proteins containing an epitope identical or substantially similar to an epitope of a protein associated with cells characterizing an autoimmune disease; proteins whose presence will compensate for an absent non-functional or partially functioning protein in an individual; and proteins that provide a therapeutic effect in an individual. 41. Композиция по п. 39, отличающаяся тем, что патоген представляет собой вирус, выбранный из группы, состоящей из вируса иммунодефицита человека (HIV); вируса Т-клеточного лейкоза человека (HTLV); вируса гриппа; вируса гепатита A (HAV); вируса гепатита В (HBV); вируса гепатита С (HCV); вируса папилломы человека (HPV); вируса простого герпеса 1 (HSVI); вируса простого герпеса 2 (HSV2); цитомегаловируса (CMV); вируса Эпштейна-Барра (EBV); риновируса и коронавируса. 41. The composition according to p. 39, wherein the pathogen is a virus selected from the group consisting of human immunodeficiency virus (HIV); human T-cell leukemia virus (HTLV); influenza virus; hepatitis A virus (HAV); hepatitis B virus (HBV); hepatitis C virus (HCV); human papillomavirus (HPV); herpes simplex virus 1 (HSVI); herpes simplex virus 2 (HSV2); cytomegalovirus (CMV); Epstein-Barr virus (EBV); rhinovirus and coronavirus. 42. Композиция по п. 39, отличающаяся тем, что молекула нуклеиновой кислоты представляет собой ДНК-последовательность, кодирующую структурные белки gag и ро1 ВИЧ с делецией psi, причем последовательность ДНК, кодирующая gag и po1, операбельно связанную с усилителем вируса саркомы Рауса, непосредственно ранним промотором цитомегаловируса, малым сигналом полиаденилирования SV 40 и необязательно с точкой начала репликации SV 40. 42. The composition according to p. 39, wherein the nucleic acid molecule is a DNA sequence encoding the structural proteins gag and po1 of HIV with a deletion of psi, the DNA sequence encoding gag and po1 operably linked to an amplifier of the Routh sarcoma virus, directly an early cytomegalovirus promoter, a small SV 40 polyadenylation signal, and optionally with an SV 40 origin of replication. 43. Композиция по п. 39, отличающаяся тем, что молекула нуклеиновой кислоты представляет собой молекулу ДНК, включающую последовательность ДНК, кодирующую белки rev, vpu и env ВИЧ, операбельно связанную с усилителем вируса саркомы Рауса, непосредственно ранним промотором цитомегаловируса, малым сигналом полиаденилирования SV 40 и необязательно точкой начала репликации SV 40. 43. The composition according to p. 39, wherein the nucleic acid molecule is a DNA molecule comprising a DNA sequence encoding HIV rev, vpu and env proteins operably linked to an Routh sarcoma virus enhancer, directly an early cytomegalovirus promoter, a small polyadenylation signal SV 40 and optionally the start point of SV 40 replication. 44. Композиция по п. 39, отличающаяся тем, что усилитель функции полинуклеотида представлен бупивакаином. 44. The composition of claim 39, wherein the polynucleotide function enhancer is bupivacaine. 45. Фармацевтический набор для иммунизации, включающий первый инокулят, содержащий фармацевтически приемлемый носитель или разбавитель и молекулу первой нуклеиновой кислоты, включающую нуклеотидную последовательность, кодирующую по меньшей мере один белок ВИЧ, операбельно связанную с регуляторными последовательностями, причем нуклеотидная последовательность способна экспрессироваться в клетках человека, второй инокулят, содержащий фармацевтический приемлемый носитель или разбавитель и молекулу второй нуклеиновой кислоты, включающую нуклеотидную последовательность, кодирующую по меньшей мере один белок ВИЧ, операбельно связанную с регуляторными последовательностями, причем нуклеотидная последовательность способна экспрессироваться в клетках человека. при этом молекула первой нуклеиновой кислоты неидентична молекуле второй нуклеиновой кислоты. 45. A pharmaceutical immunization kit comprising a first inoculum comprising a pharmaceutically acceptable carrier or diluent and a first nucleic acid molecule comprising a nucleotide sequence encoding at least one HIV protein operably linked to regulatory sequences, the nucleotide sequence being able to be expressed in human cells, a second inoculum comprising a pharmaceutically acceptable carrier or diluent and a second nucleic acid molecule, including boiling nucleotide sequence encoding at least one HIV protein operably linked to regulatory sequences, wherein the nucleotide sequence is capable of being expressed in human cells. wherein the first nucleic acid molecule is not identical to the second nucleic acid molecule. 46. Набор по п. 45, отличающийся тем, что первый и второй инокуляты включают усилитель функции полинуклеотида или упомянутый фармацевтический набор дополнительно включает третий инокулят, содержащий усилитель функции полинуклеотида. 46. The kit of claim 45, wherein the first and second inoculums comprise a polynucleotide function enhancer or said pharmaceutical kit further comprises a third inoculum comprising a polynucleotide function enhancer. 47. Набор для иммунизации по п. 45, отличающийся тем, что молекула первой нуклеиновой кислоты и молекула второй нуклеиновой кислоты вместе кодируют белки gag, pol и env ВИЧ. 47. The immunization kit according to claim 45, wherein the first nucleic acid molecule and the second nucleic acid molecule together encode HIV gag, pol and env proteins. 48. Набор для иммунизации по п. 45, отличающийся тем, что включает первый инокулят, содержащий первую фармацевтическую композицию, включающую молекулу ДНК, которая содержит последовательность ДНК, кодирующую структурные белки gag и pol ВИЧ с делецией psi, причем упомянутая последовательность, кодирующая gag и pol, операбельно связана с усилителем вируса саркомы Pa- уса, непосредственно ранним промотором цитомегаловируса, малым сигналом полиаденилирования SV 40 и необязательно с точкой начала репликации SV 40; второй инокулят, содержащий вторую фармацевтическую композицию, включающую молекулу ДНК, которая содержит последовательность ДНК, кодирующую белки rev, vpu и env ВИЧ, операбельно связанную с усилителем вируса саркомы Рауса, непосредственно ранним промотором цитомегаловируса, малым сигналом полиаденилирования SV 40 и необязательно с точкой начала репликации SV 40. 48. The immunization kit according to claim 45, characterized in that it comprises a first inoculum containing a first pharmaceutical composition comprising a DNA molecule that contains a DNA sequence encoding the HIV gag and pol structural proteins with a psi deletion, said gag and pol is operably linked to an amplifier of the Pauss sarcoma virus, directly an early cytomegalovirus promoter, a small SV 40 polyadenylation signal, and optionally with an SV 40 origin of replication; a second inoculum containing a second pharmaceutical composition comprising a DNA molecule that contains a DNA sequence encoding HIV rev, vpu and env proteins operably linked to an Routh sarcoma virus enhancer, directly an early cytomegalovirus promoter, a small SV 40 polyadenylation signal, and optionally with a replication origin SV 40.
RU95117922/14A 1993-01-26 1994-01-26 Compositions and methods of genetic material delivery RU2174845C2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US834293A 1993-01-26 1993-01-26
US08/008,342 1993-01-26
US08/008.342 1993-01-26
US2933693A 1993-03-11 1993-03-11
US08/029,336 1993-03-11
US08/029.336 1993-03-11
US08/093.235 1993-07-15
US08/125.012 1993-09-21
US08/124.962 1993-09-21

Publications (2)

Publication Number Publication Date
RU95117922A true RU95117922A (en) 1998-02-10
RU2174845C2 RU2174845C2 (en) 2001-10-20

Family

ID=26678092

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95117922/14A RU2174845C2 (en) 1993-01-26 1994-01-26 Compositions and methods of genetic material delivery

Country Status (2)

Country Link
US (4) US5593972A (en)
RU (1) RU2174845C2 (en)

Families Citing this family (484)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US20030186913A1 (en) * 1990-03-21 2003-10-02 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US20030113347A1 (en) * 1991-05-08 2003-06-19 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
DE69332485T2 (en) * 1992-08-11 2003-11-13 Harvard College Immunomodulatory peptides
GB9224584D0 (en) 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
ATE302854T1 (en) * 1993-01-26 2005-09-15 Univ Pennsylvania COMPOSITIONS AND METHODS FOR ADMINISTRATION OF GENETIC MATERIAL
US7001759B1 (en) 1993-01-26 2006-02-21 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5981505A (en) * 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
WO1994027435A1 (en) * 1993-06-01 1994-12-08 Life Technologies, Inc. Genetic immunization with cationic lipids
US6652850B1 (en) 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
US6348449B1 (en) * 1993-09-21 2002-02-19 The Trustees Of The University Of Pennsylvania Methods of inducing mucosal immunity
US6133244A (en) 1993-10-22 2000-10-17 Institut Pasteur Method for immunization against hepatitis B
FR2711670B1 (en) 1993-10-22 1996-01-12 Pasteur Institut Nucleotide vector, composition containing it and vaccine for immunization against hepatitis.
WO1995016705A1 (en) * 1993-12-15 1995-06-22 The Trustees Of The University Of Pennsylvania Vpr receptor protein
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US7732423B2 (en) * 1994-04-27 2010-06-08 Institut Pasteur Nucleotide vector, composition containing such vector, and vaccine for immunization against hepatitis
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6235888B1 (en) 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US20030220276A1 (en) * 1995-05-16 2003-11-27 Opendra Narayan HIV vaccine and method of use
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
US5668267A (en) 1995-05-31 1997-09-16 Washington University Polynucleotides encoding mammaglobin, a mammary-specific breast cancer protein
US5922836A (en) * 1995-05-31 1999-07-13 Washington University Mammaglobin antigens
US6566072B1 (en) 1995-05-31 2003-05-20 Washington University Mammaglobin, a secreted mammary-specific breast cancer protein
RU2189254C2 (en) * 1995-06-06 2002-09-20 Америкэн Хоум Продактс Корпорэйшн Vaccines against hepatitis viruses
US7176186B1 (en) * 1997-09-16 2007-02-13 The University Of Pittsburgh Of The Commonwealth System Of Higher Education Stimulation of cell-mediated immune responses by targeted particulate genetic immunization
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US6310046B1 (en) * 1995-11-17 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Sequestrin of Plasmodium falciparum
US5888767A (en) * 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
WO1997025860A1 (en) * 1996-01-19 1997-07-24 Allegheny University Of The Health Sciences Cellular immunogens useful as cancer vaccines
US6365151B1 (en) 1996-01-19 2002-04-02 Philadelphia Health And Educational Corporation Cellular immunogens comprising cognate proto-oxogenes
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US5851804A (en) * 1996-05-06 1998-12-22 Apollon, Inc. Chimeric kanamycin resistance gene
WO1997044446A1 (en) * 1996-05-24 1997-11-27 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
US6444444B1 (en) * 1996-07-10 2002-09-03 Aventis Pasteur Limited Genes encoding mycobacterial proteins associated with cell binding and cell entry and uses thereof
FR2751222B1 (en) * 1996-07-16 1998-10-09 Capsulis COMPOSITIONS CONTAINING AT LEAST ONE NUCLEIC ACID AND THEIR APPLICATIONS IN THE BIOMEDICAL FIELD, PARTICULARLY IN GENE THERAPY
JP2001505763A (en) 1996-08-09 2001-05-08 バイラル・テクノロジーズ・インコーポレーテツド HIV P-17 peptide fragment, composition containing the same, and methods for producing and using the same
US6093400A (en) * 1996-08-09 2000-07-25 Cel Sci Corporation Modified HGP-30 peptides, conjugates, compositions and methods of use
US7384923B2 (en) * 1999-05-14 2008-06-10 Lipoxen Technologies Limited Liposomes
ATE228824T1 (en) * 1996-09-13 2002-12-15 Lipoxen Technologies Ltd LIPOSOME COMPOSITION
WO1998017323A1 (en) 1996-10-23 1998-04-30 The Trustees Of The University Of Pennsylvania Improved vaccines
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
ES2195317T3 (en) * 1997-01-30 2003-12-01 Chiron Corp USE OF MICROPARTICLES WITH ADSORBED ANTIGEN TO STIMULATE IMMUNE RESPONSES.
CA2223029A1 (en) * 1997-02-12 1998-08-12 Akzo Nobel Nv Canine parvovirus dna vaccines
US7098306B2 (en) * 1997-02-13 2006-08-29 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
AU6435398A (en) * 1997-02-13 1998-09-08 University Of California, Los Angeles Prevention and treatment of hepatocellular cancer
WO1998035562A1 (en) * 1997-02-14 1998-08-20 Merck & Co., Inc. Polynucleotide vaccine formulations
US20040242522A1 (en) * 1997-02-14 2004-12-02 Volkin David B. Polynucleotide vaccine formulations
US20030118601A1 (en) * 1997-03-11 2003-06-26 Neil James Charles FIV vaccine
GB9708526D0 (en) * 1997-04-25 1997-06-18 Royal Free Hosp School Med Eukaryotic gene expression cassette and uses thereof
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
US20070010471A1 (en) * 1997-05-02 2007-01-11 Opendra Narayan HIV DNA vaccine
KR100220645B1 (en) * 1997-07-04 1999-09-15 구광시 Process for producing benzene derivatives
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US6818627B1 (en) * 1997-08-14 2004-11-16 The Trustees Of The University Of Pennsylvania Functional fragments of HIV-1 Vpr protein and methods of using the same
CA2304125A1 (en) 1997-09-18 1999-03-25 Velpandi Ayyavoo Attenuated vif dna immunization cassettes for genetic vaccines
US6699478B1 (en) * 1997-09-19 2004-03-02 Wyeth Holdings Corporation Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
CA2306733A1 (en) 1997-10-28 1999-05-06 American Home Products Corporation Compositions and methods for delivery of genetic material
US6596539B1 (en) 1997-10-31 2003-07-22 Maxygen, Inc. Modification of virus tropism and host range by viral genome shuffling
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
WO1999028475A2 (en) 1997-11-28 1999-06-10 Genset Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
US7078500B1 (en) * 1998-01-30 2006-07-18 The General Hospital Corporation Genetic immunization with nonstructural proteins of hepatitis C virus
CN101126094A (en) * 1998-01-30 2008-02-20 总医院有限公司 Genetic immunization with nonstructural proteins of hepatitis c virus
US7390619B1 (en) * 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US6573101B1 (en) * 1998-02-12 2003-06-03 The Regents Of The University Of California Compositions for receptor/liposome mediated transfection and methods of using same
EP1060247B2 (en) 1998-02-24 2011-10-26 Sisters of Providence in Oregon Ox-40 receptor binding agent for use in methods for enhancing tumour antigen-specific immune response
KR20070039615A (en) 1998-02-27 2007-04-12 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Vaccines, immunotherapeutics and methods for using the same
ATE490980T1 (en) 1998-03-19 2010-12-15 Human Genome Sciences CYTOKINE RECEPTOR SIMILAR TO THE COMMON GAMMA CHAIN
US6844188B1 (en) * 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
CA2295510A1 (en) * 1998-05-06 1999-11-11 Transgene S.A. Use of a nuclease inhibitor or interleukin-10 (il-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy
US6803035B2 (en) * 1998-05-08 2004-10-12 Arkion Life Sciences Anti-diarrheal and method for using the same
WO1999064074A1 (en) * 1998-06-11 1999-12-16 The Trustees Of The University Of Pennsylvania Methods and compositions for delivering proteins to macrophage cells and cells of macrophage derived lineage
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6264940B1 (en) * 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
EP0998945A1 (en) * 1998-09-30 2000-05-10 Transgene S.A. Use of magnesium (Mg2+) for the enhancement of gene delivery in gene therapy
WO2000025820A1 (en) * 1998-11-04 2000-05-11 Pharmadigm, Inc. Compounds and methods for genetic immunization
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
AU2215700A (en) * 1998-12-29 2000-07-31 University Of Vermont And State Agricultural College, The Use of cd40 engagement to alter t cell receptor usage
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
ATE384795T1 (en) * 1998-12-31 2008-02-15 Novartis Vaccines & Diagnostic MODIFIED HIV ENV POLYPEPTIDES
WO2000039302A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
EP1141314A2 (en) * 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2361601A1 (en) * 1999-02-08 2000-08-10 Cheryl Goldbeck Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
KR20010103788A (en) 1999-03-03 2001-11-23 멕코나시 에블린 에이치. Vaccines and Gene Therapy Compositions and Methods of Making and Using the Same
ATE529130T1 (en) * 1999-04-08 2011-11-15 Intercell Usa Inc DRY FORMULATION FOR TRANSCUTANE IMMUNIZATION
KR20010112944A (en) 1999-04-21 2001-12-22 이곤 이 버그 Methods and compositions for inhibiting the function of polynucleotide sequences
CN1196495C (en) 1999-04-30 2005-04-13 宾夕法尼亚大学理事会 Mutant human CD80 and copositions for and methods of making and using the same
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
CN1192799C (en) 1999-05-13 2005-03-16 惠氏控股有限公司 Adjuvant combination formulations
US20030232060A1 (en) * 1999-07-28 2003-12-18 Smith Stephen M. Attenuated, doxycycline-inducible human immunodeficiency virus proviral molecular clones
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
DE60039786D1 (en) * 1999-12-22 2008-09-18 Univ Pennsylvania COSMID DNA CONSTRUCTS AND METHODS FOR THEIR PREPARATION AND USE
WO2001045639A2 (en) * 1999-12-22 2001-06-28 The Ohio State University Research Foundation Methods for protecting against lethal infection with bacillus anthracis
EP1254212A2 (en) 2000-02-09 2002-11-06 Genvec, Inc. Methods of preparing and using a viral vector library
US8623379B2 (en) * 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
WO2002072754A2 (en) * 2001-03-08 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva expressing modified hiv envelope, gag, and pol genes
CA2401974C (en) 2000-03-02 2013-07-02 Emory University Dna expression vectors and methods of use
JP2003530839A (en) 2000-04-12 2003-10-21 プリンシピア ファーマスーティカル コーポレイション Albumin fusion protein
AU2001265154A1 (en) * 2000-05-31 2001-12-11 Genvec, Inc. Method and composition for targeting an adenoviral vector
US7910716B2 (en) * 2000-07-07 2011-03-22 Medical Research Council Nucleic acids encoding modified South African HIV-1 subtype C gag proteins
EP1301637B1 (en) * 2000-07-14 2008-06-11 The Trustees Of The University Of Pennsylvania Dna vaccines encoding hiv accessory proteins
AU8467201A (en) * 2000-07-27 2002-02-13 Univ Pennsylvania Compositions for and methods of using herpes simplex virus glycoprotein d to suppress immune responses
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
RU2286172C2 (en) * 2000-08-17 2006-10-27 Трипеп Аб Ribavirin-containing vaccines and methods for their application
BR0113512A (en) 2000-08-25 2005-05-10 Basf Plant Science Gmbh Plant polynucleotides encoding new prenyl proteases
EP1322338A4 (en) 2000-10-04 2005-04-13 Univ Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
BR0115271A (en) * 2000-11-10 2005-12-13 Wyeth Corp Antigenic composition, a method for enhancing the ability of an antigenic composition to elicit a vertebrate host's immune response, to elicit cytotoxic t lymphocytes in a vertebrate host, to elicit a therapeutic or prophylactic cancer effect in a vertebrate host, to moderate a allergic response in a vertebrate host, and in preventing or treating disease characterized by amyloid deposition in a vertebrate host, and adjuvant formulation
US20020094337A1 (en) * 2000-11-16 2002-07-18 University Of Maryland, Baltimore Prevention of recurrent viral disease
US6892140B1 (en) * 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
US20030162733A1 (en) * 2000-11-27 2003-08-28 Haynes Joel R. Nucleic acid adjuvants
AU2002250071B2 (en) * 2001-02-13 2008-02-14 Government Of The United States, As Represented By The Secretary Of The Army Vaccine for transcutaneous immunization
US20040028651A1 (en) * 2001-03-29 2004-02-12 Karrupiah Muthumani Composition and methods of using hiv vpr
US20070128229A1 (en) * 2002-04-12 2007-06-07 Wyeth Surface proteins of Streptococcus pyogenes
WO2002083859A2 (en) * 2001-04-13 2002-10-24 Wyeth Surface proteins of streptococcus pyogenes
WO2002083704A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
EP2277897A1 (en) 2001-04-16 2011-01-26 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
US20020193295A1 (en) * 2001-05-04 2002-12-19 Emanuel Calenoff Immunogenic peptides and uses thereof
AU2002329176A1 (en) * 2001-05-25 2002-12-23 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
EP2292772A1 (en) * 2001-07-05 2011-03-09 Novartis Vaccines and Diagnostics, Inc. HIV vaccination with a DNA encoding a HIV polypeptide and a HIV polypeptide
JP5033303B2 (en) 2001-07-05 2012-09-26 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Polynucleotides encoding polypeptides with antigenic type C HIV, polypeptides and uses thereof
JP2005521380A (en) * 2001-08-31 2005-07-21 カイロン コーポレイション Polynucleotide encoding antigenic type B HIV polypeptide, polypeptide and use thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
EP3254687A1 (en) 2001-10-04 2017-12-13 Genetics Institute LLC Methods and compositions for modulating interleukin-21 receptor activity
AU2002362753B9 (en) * 2001-10-05 2008-05-15 The Trustees Of The University Of Pennsylvania Compositions for and methods of treating and preventing sirs/sepsis
ATE382365T1 (en) * 2001-10-26 2008-01-15 Rhode Island Hospital THYMOSINE AUGMENTATION IN GENETIC IMMUNIZATION
ATE521623T1 (en) 2001-11-14 2011-09-15 Us Gov Health & Human Serv NEW GENE EXPRESSED IN PROSTATE CANCER AND METHOD OF USE
US20050019752A1 (en) * 2001-11-16 2005-01-27 Genoveffa Franchini Novel chimeric rev, tat, and nef antigens
WO2003050914A1 (en) * 2001-12-05 2003-06-19 E-Tenna Corporation Capacitively-loaded bent-wire monopole on an artificial magnetic conductor
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
WO2003067399A2 (en) * 2002-02-07 2003-08-14 Byington Carrie L Method for creating and using a treatment protocol
CN100593544C (en) * 2002-03-15 2010-03-10 惠氏控股有限公司 Mutants of the P4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
US20040180438A1 (en) 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
US20060094006A1 (en) * 2002-05-01 2006-05-04 Genoveffa Franchini Immunotherapy regimens in hiv-infected patients
US20030206916A1 (en) * 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
WO2003093449A2 (en) * 2002-05-06 2003-11-13 Nucleonics, Inc. Methods for delivery of nucleic acids
JP3660650B2 (en) * 2002-06-13 2005-06-15 株式会社東芝 Manufacturing method of semiconductor device
WO2004000217A2 (en) * 2002-06-20 2003-12-31 The Trustees Of The University Of Pennsylvania Vaccines for suppressing ige-mediated allergic disease and methods for using the same
WO2004011624A2 (en) * 2002-07-31 2004-02-05 Nucleonics, Inc. Double stranded rna structures and constructs, and methods for generating and using the same
US20040116370A1 (en) * 2002-08-30 2004-06-17 Genteric, Inc. Retroductal salivary gland genetic vaccination
AU2003262922A1 (en) * 2002-08-30 2004-03-19 Genteric, Inc. Retroductal salivary gland genetic vaccination
AU2003275127A1 (en) 2002-09-19 2004-04-08 Merial Limited P. ariasi polypeptides, p. perniciosus polypeptides and methods of use
JP2006503914A (en) * 2002-10-21 2006-02-02 エムジーアイ ファーマ バイオロジックス インコーポレイテッド Compositions and methods for treating human papillomavirus-mediated diseases
EP2085467B1 (en) 2002-10-29 2013-12-11 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Lutzomyia Longipalpis polypeptides and methods of use
JP2006515277A (en) 2002-10-29 2006-05-25 コーリー ファーマシューティカル グループ， リミテッド Methods and products for treatment and prevention of hepatitis C virus infection
US7455841B2 (en) * 2002-11-19 2008-11-25 The Trustees Of The University Of Pennsylvania Genetic constructs and compositions comprising RRE and CTE and uses thereof
ES2416629T3 (en) * 2002-12-03 2013-08-02 University Of Massachusetts Polyvalent primary HIV-1 glycoprotein DNA vaccines and vaccination procedures
AU2003227380A1 (en) * 2003-01-05 2004-07-29 Obschestvo S Ogranichennoi Otvetstvennostiju "Genno-Inzhenernye Tekhnologii 2000" Complementation method for producing rna-containing virus-like particles of hepatotropic viruses
WO2004065551A2 (en) * 2003-01-21 2004-08-05 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (mgat3), and uses thereof
JP2006522022A (en) 2003-02-14 2006-09-28 ザ キュレイターズ オブ ザ ユニバーシティー オブ ミズーリ Contraceptive methods and compositions associated with proteasome interference
WO2004093906A1 (en) * 2003-03-26 2004-11-04 Wyeth Immunogenic composition and methods
NZ543654A (en) * 2003-05-23 2009-05-31 Wyeth Corp GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
WO2005014806A2 (en) 2003-06-12 2005-02-17 Nucleonics, Inc. Conserved hbv and hcv sequences useful for gene silencing
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
WO2004112706A2 (en) 2003-06-13 2004-12-29 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
US20050106159A1 (en) * 2003-08-12 2005-05-19 Thompson Stuart A. Campylobacter jejuni outer membrane protein immunogenic composition
JP2007503205A (en) * 2003-08-22 2007-02-22 ニュークレオニクス・インコーポレイテッド Multi-compartment eukaryotic expression system
EA012066B1 (en) * 2003-10-10 2009-08-28 Паудерджект Вэксинс, Инк. Method of eliciting a t cell response
US7625753B2 (en) * 2003-12-23 2009-12-01 Cythera, Inc. Expansion of definitive endoderm cells
US8647873B2 (en) 2004-04-27 2014-02-11 Viacyte, Inc. PDX1 expressing endoderm
US20050266554A1 (en) * 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
CN103898047B (en) 2003-12-23 2020-03-03 维亚希特公司 Definitive endoderm
US7541185B2 (en) * 2003-12-23 2009-06-02 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
US8586357B2 (en) * 2003-12-23 2013-11-19 Viacyte, Inc. Markers of definitive endoderm
US7985585B2 (en) 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
EP2377922B1 (en) 2004-04-27 2020-04-08 Viacyte, Inc. PDX1 expressing endoderm
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
AU2005247910A1 (en) * 2004-05-21 2005-12-08 Wyeth Altered fibronectin-binding protein of Staphylococcus aureus
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
EP1786896B1 (en) 2004-07-09 2018-01-10 Viacyte, Inc. Methods for identifying factors for differentiating definitive endoderm
US7862829B2 (en) * 2004-07-09 2011-01-04 University Of North Carolina At Chapel Hill Viral adjuvants
MX2007001772A (en) * 2004-08-13 2007-07-11 Univ Georgia Res Found Compositions and methods for self-renewal and differentiation in human embryonic stem cells.
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
EP1784492B1 (en) 2004-08-23 2010-10-06 Alnylam Pharmaceuticals, Inc. Multiple rna polymerase iii promoter expression constructs
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
US20060057184A1 (en) * 2004-09-16 2006-03-16 Nycz Jeffrey H Process to treat avascular necrosis (AVN) with osteoinductive materials
AU2005289633A1 (en) 2004-09-24 2006-04-06 Nucleonics, Inc. Targeting opposite strand replication intermediates of single-stranded viruses by RNAi
AU2005333603A1 (en) 2004-10-21 2007-01-04 Wyeth Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
GB0423974D0 (en) * 2004-10-28 2004-12-01 Ares Trading Sa Proteins
WO2007050095A2 (en) * 2004-11-19 2007-05-03 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
CA2592099A1 (en) 2004-12-22 2006-06-29 Nucleonics, Inc. Conserved hbv and hcv sequences useful for gene silencing
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
CA2597921A1 (en) * 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines
AU2006216671A1 (en) * 2005-02-23 2006-08-31 The Uab Research Foundation Alkyl-glycoside enhanced vaccination
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
WO2007031867A2 (en) * 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-stru tural ns3/4a fusion gene
EP1928537B1 (en) 2005-09-02 2015-01-21 Intercell USA, Inc. Devices for transcutaneous delivery of vaccines and transdermal delivery of drugs
DK2674485T3 (en) 2005-10-27 2019-08-26 Viacyte Inc PDX-1 EXPRESSING DORSAL AND VENTRAL FORTARM ENDODERM
MX2008005405A (en) * 2005-10-28 2008-09-11 Florida Internat University Bo Horse: human chimeric antibodies.
ES2374458T3 (en) * 2006-01-13 2012-02-16 The Trustees Of The University Of Pennsylvania IMMUNOTHERAPEUTIC VACCINES AND AGENTS USING OPTIMIZED IL-15 IN CODONS, AND METHODS FOR USING THEMSELVES.
WO2007082105A2 (en) 2006-01-16 2007-07-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chlamydia vaccine
UY30097A1 (en) 2006-01-20 2007-08-31 Atugen Ag THERAPEUTIC USES OF RTP801 INHIBITORS
DK2650360T3 (en) * 2006-03-02 2019-10-07 Viacyte Inc Endocrine precursor cells, pancreatic hormone-expressing cells, and methods of preparation
US11254916B2 (en) 2006-03-02 2022-02-22 Viacyte, Inc. Methods of making and using PDX1-positive pancreatic endoderm cells
US7695965B2 (en) 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
EP2397855A3 (en) 2006-03-14 2012-03-14 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
WO2007127454A2 (en) * 2006-04-28 2007-11-08 Cythera, Inc. Hepatocyte lineage cells
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2495307B9 (en) 2006-07-13 2018-05-02 Wyeth LLC Production of coagulation factor IX with improved glycosylation pattern
EP2594576B1 (en) 2006-07-28 2015-07-01 The Trustees of The University of Pennsylvania Improved HIV vaccines
US20100323442A1 (en) * 2006-10-17 2010-12-23 Emmanuel Edward Baetge Modulation of the phosphatidylinositol-3-kinase pathway in the differentiation of human embryonic stem cells
JP2010507387A (en) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド Novel siRNA and method of using the same
EP2444410A3 (en) 2007-02-28 2012-08-08 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
US20090214593A1 (en) * 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
US8071561B2 (en) * 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
US7855049B2 (en) 2007-08-31 2010-12-21 Biocrine Ab Inositol pyrophosphates determine exocytotic capacity
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
EP2612868B1 (en) 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
KR101255419B1 (en) * 2007-11-12 2013-04-17 이노비오 파마수티컬즈, 인크. Novel vaccines against multiple subtypes of influenza virus
EP2209490A4 (en) * 2007-11-14 2013-01-09 VGX Pharmaceuticals LLC Antibody production elicited by a dna vaccine delivered by electroporation
AU2009210624A1 (en) 2008-01-11 2009-08-13 Vgx Pharmaceuticals, Inc. Novel vaccines against multiple subtypes of dengue virus
AU2009231598B2 (en) 2008-04-04 2015-03-12 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same
KR101589511B1 (en) * 2008-04-04 2016-02-01 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Consensus Sequences of Chikungunya Viral Proteins, Nucleic Acid Molecules Encoding the Same, and Compositions and Methods for Using the Same
US8535687B2 (en) * 2008-05-28 2013-09-17 The Trustees Of The University Of Pennsylvania Smallpox DNA vaccine and the antigens therein that elicit an immune response
CA2635187A1 (en) * 2008-06-05 2009-12-05 The Royal Institution For The Advancement Of Learning/Mcgill University Oligonucleotide duplexes and uses thereof
EP2293800B1 (en) 2008-06-06 2016-10-05 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
CA2728308A1 (en) 2008-06-20 2009-12-23 Wyeth Llc Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
AU2008363596B2 (en) 2008-10-29 2015-04-30 Inovio Pharmaceuticals, Inc Improved HCV vaccines and methods for using the same
US8921536B2 (en) 2008-10-29 2014-12-30 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
RU2478396C2 (en) 2008-11-05 2013-04-10 ВАЙЕТ ЭлЭлСи MULTI-COMPONENT IMMUNOGENIC COMPOSITION FOR PREVENTING DOSEASE, CAUSED BY β-HEMOLYTIC STREPTOCCOCI (BHS)
US8278106B2 (en) 2008-11-14 2012-10-02 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
EP2358733B1 (en) 2008-11-17 2015-07-08 Inovio Pharmaceuticals, Inc. Antigens that elicit immune response against flavivirus and methods of using same
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
US20110288155A1 (en) 2008-12-18 2011-11-24 Elena Feinstein Sirna compounds and methods of use thereof
CA2653478A1 (en) 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
US9050287B2 (en) 2009-01-23 2015-06-09 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
CN106924728B (en) * 2009-05-22 2021-02-05 健诺西生物科学公司 Vaccines against herpes simplex type ii virus: compositions and methods for eliciting an immune response
WO2010144336A2 (en) 2009-06-08 2010-12-16 Quark Pharmaceuticals, Inc. Methods for treating chronic kidney disease
CN102821790A (en) 2009-09-14 2012-12-12 宾夕法尼亚大学托管会 Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
JP5955771B2 (en) 2009-10-22 2016-07-20 トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ Cell-based anticancer composition and methods for making and using the same
CN106987595B (en) 2009-11-02 2021-07-06 宾夕法尼亚大学托管会 Foot and Mouth Disease Virus (FMDV) consensus proteins, their coding sequences and vaccines prepared therefrom
WO2011063263A2 (en) 2009-11-20 2011-05-26 Oregon Health & Science University Methods for producing an immune response to tuberculosis
US9028809B2 (en) 2009-11-24 2015-05-12 Takeda Vaccines, Inc. Compositions, methods and uses for expression of enterobacterium-associated peptides
TW201124160A (en) 2009-11-26 2011-07-16 Quark Pharmaceuticals Inc SiRNA compounds comprising terminal substitutions
EP2862929B1 (en) 2009-12-09 2017-09-06 Quark Pharmaceuticals, Inc. Compositions and methods for treating diseases, disorders or injury of the CNS
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
AU2011213559B2 (en) 2010-02-08 2015-05-07 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding RANTES, and compositions comprising and methods of using the same
WO2011112599A2 (en) 2010-03-12 2011-09-15 The United States Of America, As Represented By The Secretary. Department Of Health & Human Services Immunogenic pote peptides and methods of use
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
DK2580243T3 (en) 2010-06-09 2020-01-13 Genmab As ANTIBODIES AGAINST HUMAN CD38
ME02919B (en) 2010-06-15 2018-04-20 Genmab As Human antibody drug conjugates against tissue factor
WO2011163436A1 (en) 2010-06-24 2011-12-29 Quark Pharmaceuticals, Inc. Double stranded rna compounds to rhoa and use thereof
US8927692B2 (en) 2010-11-12 2015-01-06 The Trustees Of The University Of Pennsylvania Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
WO2012074881A2 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
SG190412A1 (en) 2010-12-06 2013-06-28 Quark Pharmaceuticals Inc Double stranded oligonucleotide compounds comprising threose modifications
EP2670443A4 (en) 2011-01-31 2015-10-14 Univ Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
WO2012109668A1 (en) 2011-02-11 2012-08-16 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
EP2492279A1 (en) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
US9796979B2 (en) 2011-03-03 2017-10-24 Quark Pharmaceuticals Inc. Oligonucleotide modulators of the toll-like receptor pathway
CN103562387A (en) 2011-03-03 2014-02-05 夸克医药公司 Oligonucleotide modulators of the toll-like receptor pathway
RS57397B8 (en) 2011-06-10 2020-01-31 Univ Oregon Health & Science Cmv glycoproteins and recombinant vectors
KR102314421B1 (en) 2011-07-11 2021-10-19 이노비오 파마수티컬즈, 인크. Cross-protective arenavirus vaccines and their method of use
DK2734544T3 (en) 2011-07-18 2021-03-15 Us Health METHODS AND COMPOSITIONS FOR INHIBITION OF POLYOMAVIRUS ASSOCIATED PATHOLOGY
WO2013039792A1 (en) 2011-09-12 2013-03-21 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunogens based on an hiv-1 gp120 v1v2 epitope
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
KR20140076613A (en) 2011-10-12 2014-06-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Vaccines for human papilloma virus and methods for using the same
KR101913674B1 (en) 2011-10-24 2018-10-31 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Improved hcv vaccines and methods for using the same
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
US20140323549A1 (en) 2011-11-08 2014-10-30 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
US9624273B2 (en) 2011-11-23 2017-04-18 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
EA026926B1 (en) 2011-12-12 2017-05-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Compositions, comprising improved il-12 genetic constructs, vaccines, immunotherapeutics and methods of using the same
WO2013090294A1 (en) 2011-12-12 2013-06-20 The Trustees Of The University Of Pennsylvania Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections
RU2014125496A (en) 2012-01-12 2016-02-27 Кварк Фармасьютикалс, Инк. COMBINED THERAPY FOR TREATMENT OF HEARING DISORDERS AND EQUILIBRIUM
AU2013245950B2 (en) 2012-04-10 2016-04-21 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
AU2013245729B2 (en) 2012-04-12 2016-09-29 The Trustees Of The University Of Pennsylvania Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
US9738879B2 (en) 2012-04-27 2017-08-22 Duke University Genetic correction of mutated genes
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
ES2631608T3 (en) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Env-glycoprotein variant of HIV-1
EP2698377A1 (en) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Enhanced rapid immunogen selection method for HIV gp120 variants
DK2895607T3 (en) 2012-09-12 2021-05-25 Quark Pharmaceuticals Inc DOUBLE-STRING OLIGONUCLEOTIDE MOLECULES FOR DDIT4 AND METHODS FOR USING IT
AU2013315524B2 (en) 2012-09-12 2019-01-31 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to p53 and methods of use thereof
EP2895191B1 (en) 2012-09-14 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury protein, adenoviral vectors encoding brachyury protein, and their use
WO2014093702A1 (en) 2012-12-12 2014-06-19 The Usa, As Represented By The Secretary, Department Of Health And Human Services Hiv therapeutics and methods of making and using same
EP4299741A3 (en) 2012-12-12 2024-02-28 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
CA2888648C (en) 2012-12-13 2021-06-08 The Trustees Of The University Of Pennsylvania Wt1 vaccine
WO2015089492A2 (en) 2013-12-13 2015-06-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
WO2014120975A1 (en) 2013-02-01 2014-08-07 California Institute Of Technology Antibody-mediated immunocontraception
EP2956169B1 (en) 2013-02-12 2018-04-11 THE UNITED STATES OF AMERICA, represented by the S Monoclonal antibodies that neutralize norovirus
CA2898522A1 (en) 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Improved vaccines for human papilloma virus and methods for using the same
WO2014145951A2 (en) 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
EP2968607B1 (en) 2013-03-15 2019-07-24 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
US10000556B2 (en) 2013-05-09 2018-06-19 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Single-domain VHH antibodies directed to norovirus GI.1 and GII.4 and their use
EP3417880A1 (en) 2013-06-05 2018-12-26 Duke University Rna-guided gene editing and gene regulation
BR112015031611A2 (en) 2013-06-17 2017-12-12 Massachusetts Inst Technology application, manipulation and optimization of systems, methods and compositions for targeting and modeling post-mitotic cell diseases and disorders
MX2015017313A (en) 2013-06-17 2016-11-25 Broad Inst Inc Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components.
EP3011031B1 (en) 2013-06-17 2020-09-30 The Broad Institute Inc. Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
EP4176897A1 (en) 2013-06-25 2023-05-10 International AIDS Vaccine Initiative, Inc. Tuberculosis compositions and methods of using the same
BR112016001775A2 (en) 2013-07-31 2017-09-05 Univ Arkansas COMPOSITION, METHODS OF TREATMENT OF A HUMAN WHO HAS BEEN DIAGNOSED WITH CANCER, OF CANCER PREVENTION IN A HUMAN AT HIGH RISK OF RECEIVING CANCER, AND OF PRODUCING A COMPOSITION OF AN ISOLATED HUMAN ANTI-TUMOR NK CELL POPULATION AND A DENDRITIC CELL POPULATION HUMAN ANTITUMOR ISOLATED, HUMAN NK AND DENDRITIC CELLS ISOLATED, E, KIT
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
ES2957209T3 (en) 2013-09-30 2024-01-15 Triad Nat Security Llc Conserved region HIV mosaic immunogenic polypeptides
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CN105813654B (en) 2013-10-11 2019-05-31 美国政府(由卫生和人类服务部的部长所代表) TEM8 antibody and application thereof
EP4219699A1 (en) 2013-12-12 2023-08-02 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
ES2765481T3 (en) 2013-12-12 2020-06-09 Broad Inst Inc Administration, use and therapeutic applications of crisp systems and compositions for genomic editing
BR112016013547A2 (en) 2013-12-12 2017-10-03 Broad Inst Inc COMPOSITIONS AND METHODS OF USE OF CRISPR-CAS SYSTEMS IN NUCLEOTIDE REPEAT DISORDERS
JP2017527256A (en) 2013-12-12 2017-09-21 ザ・ブロード・インスティテュート・インコーポレイテッド Delivery, use and therapeutic applications of CRISPR-Cas systems and compositions for HBV and viral diseases and disorders
JP2017501149A (en) 2013-12-12 2017-01-12 ザ・ブロード・インスティテュート・インコーポレイテッド Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for targeting disorders and diseases using particle delivery components
EP3079716B1 (en) 2013-12-13 2019-05-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multi-epitope tarp peptide vaccine and uses thereof
WO2015095770A1 (en) 2013-12-20 2015-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic jc polyomavirus compositions and methods of use
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2015106003A1 (en) 2014-01-08 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Ras pathways as markers of protection against hiv and methods to improve vaccine efficacy
CN106715458A (en) 2014-07-18 2017-05-24 华盛顿大学 Cancer vaccine compositions and methods of use thereof
US10934360B2 (en) 2014-07-31 2021-03-02 The Hong Kong University Of Science And Technology Human monoclonal antibodies against EPHA4 and their use
EP3686279B1 (en) 2014-08-17 2023-01-04 The Broad Institute, Inc. Genome editing using cas9 nickases
WO2016037154A1 (en) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
US10160795B2 (en) 2014-11-14 2018-12-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to Ebola virus glycoprotein and their use
US11319555B2 (en) 2014-11-20 2022-05-03 Duke University Compositions, systems and methods for cell therapy
CA2969214A1 (en) 2014-12-01 2016-06-09 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
WO2016090170A1 (en) 2014-12-05 2016-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A potent anti-influenza a neuraminidase subtype n1 antibody
EP3985115A1 (en) 2014-12-12 2022-04-20 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
WO2016100974A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
US10420834B2 (en) 2014-12-24 2019-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant metapneumovirus F proteins and their use
AU2015369725A1 (en) 2014-12-24 2017-06-29 Massachusetts Institute Of Technology CRISPR having or associated with destabilization domains
WO2016130600A2 (en) 2015-02-09 2016-08-18 Duke University Compositions and methods for epigenome editing
EP3261665A1 (en) 2015-02-24 2018-01-03 The United States of America, as represented by The Secretary, Department of Health and Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
PL3271389T3 (en) 2015-03-20 2020-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to gp120 and their use
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10624964B2 (en) 2015-05-01 2020-04-21 The Trustees Of The University Of Pennsylvania Methods and compositions for stimulating immune response using potent immunostimulatory RNA motifs
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
WO2016205745A2 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Cell sorting
CA3012631A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CA3012607A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Crispr enzymes and systems
RU2752834C2 (en) 2015-06-18 2021-08-09 Те Брод Инститьют, Инк. Crispr enzyme mutations reducing non-targeted effects
EP3325018A4 (en) 2015-07-22 2019-04-24 Duke University High-throughput screening of regulatory element function with epigenome editing technologies
AU2016308339A1 (en) 2015-08-18 2018-04-12 Baylor College Of Medicine Methods and compositions for altering function and structure of chromatin loops and/or domains
EP3341727B1 (en) 2015-08-25 2022-08-10 Duke University Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
WO2017062748A1 (en) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
US11692182B2 (en) 2015-10-09 2023-07-04 Monsanto Technology Llc RNA-guided DNA nucleases and uses thereof
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017066497A2 (en) 2015-10-13 2017-04-20 Duke University Genome engineering with type i crispr systems in eukaryotic cells
US20170211142A1 (en) 2015-10-22 2017-07-27 The Broad Institute, Inc. Novel crispr enzymes and systems
US11492670B2 (en) 2015-10-27 2022-11-08 The Broad Institute Inc. Compositions and methods for targeting cancer-specific sequence variations
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
CN108884149B (en) 2015-11-03 2022-07-01 美国政府(由卫生和人类服务部的部长所代表) HIV-1 GP41 neutralizing antibodies and uses thereof
WO2017082946A1 (en) 2015-11-13 2017-05-18 University Of Utah Research Foundation Combinatorial gene construct and non-viral delivery for anti-obesity
BR112018010639A2 (en) * 2015-11-24 2019-01-22 Glaxosmithkline Ip Dev Ltd transient transfection method for retroviral production.
WO2017089308A1 (en) * 2015-11-24 2017-06-01 Glaxosmithkline Intellectual Property Development Limited Stable cell lines for retroviral production
EA201891317A3 (en) 2015-11-30 2019-04-30 Дьюк Юниверсити THERAPEUTIC TARGETS FOR CORRECTION OF HUMAN DISTROPHIN GENE BY EDITING GENES AND METHODS OF THEIR APPLICATION
US20190233814A1 (en) 2015-12-18 2019-08-01 The Broad Institute, Inc. Novel crispr enzymes and systems
EP3397757A4 (en) 2015-12-29 2019-08-28 Monsanto Technology LLC Novel crispr-associated transposases and uses thereof
AU2017214656B2 (en) 2016-02-05 2022-08-25 Inovio Pharmaceuticals, Inc. Cancer vaccines and methods of treatment using the same
WO2017139392A1 (en) 2016-02-08 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant hiv-1 envelope proteins and their use
WO2017156272A1 (en) 2016-03-09 2017-09-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant hiv-1 envelope proteins and their use
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
US11020160B2 (en) 2016-03-21 2021-06-01 Warsaw Orthopedic, Inc. Surgical injection system and method
CN115960263A (en) 2016-03-29 2023-04-14 美国政府(由卫生和人类服务部的部长所代表) Substitution-modified pre-fusion RSV F proteins and uses thereof
EP3445853A1 (en) 2016-04-19 2019-02-27 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
SG10202010311SA (en) 2016-04-19 2020-11-27 Broad Inst Inc Novel Crispr Enzymes and Systems
CA3026110A1 (en) 2016-04-19 2017-11-02 The Broad Institute, Inc. Novel crispr enzymes and systems
US10709814B2 (en) 2016-04-22 2020-07-14 Warsaw Orthopedic, Inc. Osteoimplant comprising an insoluble fibrous polymer
WO2017192589A1 (en) 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
EP3452498B1 (en) 2016-05-05 2023-07-05 Duke University Crispr/cas-related compositions for treating duchenne muscular dystrophy
CN109890411A (en) 2016-06-16 2019-06-14 国际艾滋病疫苗行动组织公司 Tuberculosis composition and treatment or prevention method lungy
US11788083B2 (en) 2016-06-17 2023-10-17 The Broad Institute, Inc. Type VI CRISPR orthologs and systems
US11091775B2 (en) 2016-06-22 2021-08-17 Oregon Health And Science University Recombinant cytomegalovirus vectors as vaccines for tuberculosis
WO2018005873A1 (en) 2016-06-29 2018-01-04 The Broad Institute Inc. Crispr-cas systems having destabilization domain
EP4275747A3 (en) 2016-07-19 2024-01-24 Duke University Therapeutic applications of cpf1-based genome editing
CN110312799A (en) 2016-08-17 2019-10-08 博德研究所 Novel C RISPR enzyme and system
EP3500671A4 (en) 2016-08-17 2020-07-29 The Broad Institute, Inc. Novel crispr enzymes and systems
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
AU2017332161A1 (en) 2016-09-21 2019-04-04 The United States Government As Represented By The Department Of Veterans Affairs Chimeric antigen receptor (car) that targets chemokine receptor CCR4 and its use
JP2019537555A (en) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド Methods and compositions for treating herpes
WO2018067582A2 (en) 2016-10-03 2018-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 env fusion peptide immunogens and their use
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2018071576A1 (en) 2016-10-14 2018-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of tumors by inhibition of cd300f
US11078239B2 (en) 2016-10-25 2021-08-03 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Prefusion PIV F immunogens and their use
WO2018081318A1 (en) 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
EP3532616A1 (en) 2016-10-28 2019-09-04 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus
WO2018081832A1 (en) 2016-10-31 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
EP3554538A2 (en) 2016-12-16 2019-10-23 Institute for Research in Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
US11021535B2 (en) 2017-02-10 2021-06-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
AU2018234825B2 (en) 2017-03-15 2020-12-17 Massachusetts Institute Of Technology Novel CAS13B orthologues CRISPR enzymes and systems
EP3600405A1 (en) 2017-03-24 2020-02-05 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Glycan-masked engineered outer domains of hiv-1 gp120 and their use
CN110799645A (en) 2017-04-12 2020-02-14 博德研究所 Novel type VI CRISPR orthologs and systems
US20200405639A1 (en) 2017-04-14 2020-12-31 The Broad Institute, Inc. Novel delivery of large payloads
WO2018204777A2 (en) 2017-05-05 2018-11-08 The Broad Institute, Inc. Methods for identification and modification of lncrna associated with target genotypes and phenotypes
WO2019005884A1 (en) 2017-06-26 2019-01-03 The Broad Institute, Inc. Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
US11168322B2 (en) 2017-06-30 2021-11-09 Arbor Biotechnologies, Inc. CRISPR RNA targeting enzymes and systems and uses thereof
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
BR102017016440A2 (en) 2017-07-31 2019-03-19 Universidade Federal Do Rio Grande Do Sul COMPOSITION FOR CENTRAL NERVOUS SYSTEM GENE THERAPY, OBTAINING AND USE PROCESS
EP3684397A4 (en) 2017-09-21 2021-08-18 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
US20200255828A1 (en) 2017-10-04 2020-08-13 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
WO2019079337A1 (en) 2017-10-16 2019-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant hiv-1 envelope proteins and their use
EP3697806A4 (en) 2017-10-17 2021-10-27 International AIDS Vaccine Initiative, Inc. Tuberculosis antigen cassettes
US11547614B2 (en) 2017-10-31 2023-01-10 The Broad Institute, Inc. Methods and compositions for studying cell evolution
US20200291395A1 (en) 2017-11-02 2020-09-17 Arbor Biotechnologies, Inc. Novel crispr-associated transposon systems and components
WO2019108541A1 (en) 2017-11-28 2019-06-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant rsv g proteins and their use
CN117264963A (en) 2017-12-13 2023-12-22 艾诺奥医药品有限公司 PRAME-targeted cancer vaccine and uses thereof
AU2018383658B2 (en) 2017-12-13 2022-02-10 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting mesothelin and uses thereof
KR102560562B1 (en) 2017-12-13 2023-07-31 이노비오 파마수티컬즈, 인크. Cancer Vaccines Targeting MUC16 and Uses Thereof
WO2019136029A1 (en) 2018-01-02 2019-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
WO2019143934A1 (en) 2018-01-19 2019-07-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cancer activity of scbg3a2 and lps
AU2019226034A1 (en) 2018-02-21 2020-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 Env and their use
ES2953541T3 (en) 2018-03-14 2023-11-14 Arbor Biotechnologies Inc Novel CRISPR DNA and RNA Targeting Systems and Enzymes
DK3765615T3 (en) 2018-03-14 2023-08-21 Arbor Biotechnologies Inc NEW ENZYMES AND SYSTEMS FOR TARGETING CRISPR DNA
US10968257B2 (en) 2018-04-03 2021-04-06 The Broad Institute, Inc. Target recognition motifs and uses thereof
US20210198664A1 (en) 2018-05-16 2021-07-01 Arbor Biotechnologies, Inc. Novel crispr-associated systems and components
WO2020018142A1 (en) 2018-07-16 2020-01-23 Arbor Biotechnologies, Inc. Novel crispr dna targeting enzymes and systems
CN112930192A (en) 2018-08-03 2021-06-08 美国政府(由卫生和人类服务部的部长所代表) Nipah virus immunogens and uses thereof
KR20210056329A (en) 2018-08-07 2021-05-18 더 브로드 인스티튜트, 인코퍼레이티드 New CAS12B enzyme and system
US20210317429A1 (en) 2018-08-20 2021-10-14 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
US20220118077A1 (en) 2018-09-11 2022-04-21 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders
CA3117390A1 (en) 2018-10-22 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant gp120 protein with v1-loop deletion
AU2019393745A1 (en) 2018-12-04 2021-06-10 California Institute Of Technology HIV vaccine immunogens
EP3898958A1 (en) 2018-12-17 2021-10-27 The Broad Institute, Inc. Crispr-associated transposase systems and methods of use thereof
EP3883609A2 (en) 2018-12-20 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
WO2020186213A1 (en) 2019-03-14 2020-09-17 The Broad Institute, Inc. Novel nucleic acid modifiers
US20220177863A1 (en) 2019-03-18 2022-06-09 The Broad Institute, Inc. Type vii crispr proteins and systems
EP3962523A2 (en) 2019-05-03 2022-03-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
US20230085439A1 (en) 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
AU2020299382A1 (en) 2019-07-02 2022-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind EGFRvIII and their use
AU2020398658A1 (en) 2019-12-06 2022-07-07 Scribe Therapeutics Inc. Particle delivery systems
JP2023506170A (en) 2019-12-11 2023-02-15 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ Mumps virus and measles virus immunogens and their uses
JP2023513693A (en) 2020-02-11 2023-04-03 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ SARS-CoV-2 vaccine
WO2021168292A1 (en) 2020-02-20 2021-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epstein-barr virus monoclonal antibodies and uses thereof
US11213482B1 (en) 2020-03-05 2022-01-04 University of Pittsburgh—Of the Commonwealth System of Higher Educat SARS-CoV-2 subunit vaccine and microneedle array delivery system
EP4142785A2 (en) 2020-04-29 2023-03-08 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant human metapneumovirus f proteins and their use
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2022035860A2 (en) 2020-08-10 2022-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Replication-competent adenovirus type 4-hiv env vaccines and their use
WO2022188039A1 (en) 2021-03-09 2022-09-15 Huigene Therapeutics Co., Ltd. Engineered crispr/cas13 system and uses thereof
WO2022068912A1 (en) 2020-09-30 2022-04-07 Huigene Therapeutics Co., Ltd. Engineered crispr/cas13 system and uses thereof
WO2022093745A1 (en) 2020-10-26 2022-05-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
WO2022132904A1 (en) 2020-12-17 2022-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies targeting sars-cov-2
CN116917478A (en) 2020-12-22 2023-10-20 亥姆霍兹慕尼黑中心-德国健康与环境研究中心(有限公司) Use of CRISPR/CAS13 in the treatment of RNA virus and/or bacteria induced diseases
EP4277656A1 (en) 2021-01-15 2023-11-22 The United States of America, as represented by The Secretary, Department of Health and Human Services Replication-competent adenovirus type 4 sars-cov-2 vaccines and their use
AU2022221297A1 (en) 2021-02-09 2023-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies targeting the spike protein of coronaviruses
WO2022173689A1 (en) 2021-02-09 2022-08-18 University Of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
US20240041978A1 (en) 2021-03-03 2024-02-08 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services La protein as a novel regulator of osteoclastogenesis
EP4305157A1 (en) 2021-03-09 2024-01-17 Huidagene Therapeutics (Singapore) Pte. Ltd. Engineered crispr/cas13 system and uses thereof
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
WO2022232648A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion-stabilized lassa virus glycoprotein complex and its use
CA3216228A1 (en) 2021-06-09 2022-12-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
AU2022323509A1 (en) 2021-08-03 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
CA3232223A1 (en) 2021-09-17 2023-03-23 Ying Fu Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
WO2023076881A1 (en) 2021-10-26 2023-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
CN114015674A (en) 2021-11-02 2022-02-08 辉二(上海)生物科技有限公司 Novel CRISPR-Cas12i system
WO2023086961A1 (en) 2021-11-12 2023-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sars-cov-2 spike fused to a hepatitis b surface antigen
WO2023154824A1 (en) 2022-02-10 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that broadly target coronaviruses
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
WO2023192827A1 (en) 2022-03-26 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific antibodies to hiv-1 env and their use
WO2023192835A1 (en) 2022-03-27 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Base-covered hiv-1 envelope ectodomains and their use
WO2023192881A1 (en) 2022-03-28 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2023220645A1 (en) 2022-05-10 2023-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccine for human t-lymphotropic virus-1
WO2023227669A2 (en) 2022-05-26 2023-11-30 UCB Biopharma SRL Novel nucleic acid-editing proteins
WO2024003046A1 (en) 2022-06-27 2024-01-04 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Viral load-dependent crispr/cas13-system
WO2024030829A1 (en) 2022-08-01 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024054822A1 (en) 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth
WO2024064826A1 (en) 2022-09-22 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1594097A (en) * 1976-12-16 1981-07-30 Int Inst Of Differentiation Production of specific immune nucleic acids cell dialysates and antibodies
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US5036006A (en) * 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
GB8508845D0 (en) * 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5185254A (en) * 1988-12-29 1993-02-09 The Wistar Institute Gene family of tumor-associated antigens
CA2489769A1 (en) * 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
AU7312891A (en) * 1990-02-12 1991-09-03 Board Of Regents, The University Of Texas System Satellite cell proliferation in adult skeletal muscle
CA2102918C (en) * 1992-03-11 2007-05-08 Joel R. Haynes Genetic vaccine for immunodeficiency viruses
WO1993023552A1 (en) * 1992-05-21 1993-11-25 Government Of The United States As Represented By Secretary Department Of Health And Human Services Targeting gene expression to living tissue using jet injection
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization

Similar Documents

Publication Publication Date Title
RU95117922A (en) COMPOSITION AND METHODS OF DELIVERY OF GENETIC MATERIAL
CA2153593A1 (en) Compositions and methods for delivery of genetic material
Yuan et al. Human immunodeficiency virus vpr gene encodes a virion-associated protein
Terwilliger et al. Functional role of human immunodeficiency virus type 1 vpu.
Gorny et al. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody
Hel et al. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre-and postchallenge CD4+ and CD8+ T cell responses
Cohen et al. Human immunodeficiency virus vpr product is a virion-associated regulatory protein
Haigwood et al. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies
Earl et al. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140
Dowbenko et al. Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies
Michel et al. Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV--hepatitis B surface antigen particles.
Abimiku et al. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques
Byrn et al. Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4
Björling et al. Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.
Irwin et al. Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates
Shen et al. HIV-1 gp120 and modified vaccinia virus Ankara (MVA) gp140 boost immunogens increase immunogenicity of a DNA/MVA HIV-1 vaccine
Mills et al. HIV p24-specific helper T cell clones from immunized primates recognize highly conserved regions of HIV-1.
Verrier et al. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates
Morrison et al. Evidence for the cooperation of gp120 amino acids 322 and 448 in SIVmac entry
Haffar et al. HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles
Oram et al. Sequence analysis of the V3 loop regions of the env genes of Ugandan human immunodeficiency proviruses
Suh et al. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model
Conley et al. Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens
AU2003269748A1 (en) Antigenic peptides
Gallo Human retroviruses in the second decade: a personal perspective